Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lapoumeroulie, C
Right arrow Articles by Elion, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lapoumeroulie, C
Right arrow Articles by Elion, J
Haematologica, Vol 90, Issue 3, 401-403
Copyright © 2005 by Ferrata Storti Foundation

Letter

Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea

C Lapoumeroulie, M Benkerrou, MH Odievre, R Ducrocq, M Brun, and J Elion

Plasma endothelin-1 (ET-1) is elevated in patients with sickle cell disease (SCD). Hydroxyurea (HU) is the only drug with demonstrated clinical efficacy in SCD. Here we show that treatment with HU results in a decreased concentration of circulating ET-1 which is not correlated with the HU-induced increase in HbF level. Blunting of the ET-1 vasoconstrictive stimulus could contribute to the beneficial effects of HU.


This article has been cited by other articles:


Home page
 haematolHome page
M.-H. Odievre, V. Bony, M. Benkerrou, C. Lapoumeroulie, C. Alberti, R. Ducrocq, E. Jacqz-Aigrain, J. Elion, and J.-P. Cartron
Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease
Haematologica, April 1, 2008; 93(4): 502 - 510.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.